Hence, therapeutic agents targeting Nrf2 must have high specificity for Nrf2 activation, and their use for the treatment of neurodegeneration must be considered against the potential negative consequences of Nrf2 activation such as cancer promotion. The gene discussed is NFE2L2; the disease is cancer.